Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen vs Low-dose Aspirin Regimens in Coronary Atherosclerosis
NCT03230851Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Indobufen in Coronary atherosclerosis (CAD) (7 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Platelet Aggregation Rate at 1 month, Plasma Thromboxane B2 at 1 month and 1 more. Status: unknown.
02
Drugs
Indobufen
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT03230851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230851.